EUVIMEDEUVIMED entdecken
Crossref

A Review on Targeting A-Synuclein Aggregation for Parkinson’s Disease Modification

I. B. Shelke, S. S. Wanjari, A. R. Jaiswal

International Journal of Innovative Science and Research Technology · 19.03.2026 · 1365

DOI: 10.38124/ijisrt/26mar649 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Innovative Science and Research Technology, online erschienen am 19.03.2026. Verfasst von I. B. Shelke und 2 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Global Burden of Disease Study and other major global health - surveillance efforts show that parkinson’s disease (PD) has seen a sharp rise in prevelance over recent decades. In 1990, there were roughly 3.15 million people living with PD worldwide; by 2021, that number had increased to about 11.77 million - a rise of ~ 27.4%.The age - standardized prevalence rate increased from around 86 per 100,000 in 1990 to about 139 per 100,000 in 2021. According to 2019 estimates , over 8.5 million individuals globally had PD ; the disease burden - in terms of disability and mortality - also risen substantially. As of 2019, PD contributed to approximately 5.8 million disability adjusting life years and the number of ths attributed to PD was about 329,000 - reflecting more than 100% increase in PD- related deaths since 2000.Parkinson’s disease is one of the most common neurodegenerative disorders, affecting more than seven million people worldwide. It is primarily caused by the progressive degeneration of dopamine-producing neurons in specific regions of the brain, which results in a variety of motor symptoms such as tremor, rigidity, and slowed movement, along with several non-motor complications. The condition is complex and influenced by both genetic susceptibility and environmental factors that contribute to its development and prevalence in different populations. A key pathological feature of the disease is the formation of abnormal protein aggregates known as Lewy bodies within brain cells. Early diagnosis of Parkinson’s disease can be challenging because initial symptoms are often subtle and may appear years before the typical motor signs become evident. Effective management therefore requires improved diagnostic criteria, recognition of different disease subtypes, and the use of individualized treatment strategies to address the diverse clinical presentations and progression patterns of the disorder.

Zitieren

APA

Shelke, I. B., Wanjari, S. S., & Jaiswal, A. R. (2026). A Review on Targeting A-Synuclein Aggregation for Parkinson’s Disease Modification. International Journal of Innovative Science and Research Technology, 1365. https://doi.org/10.38124/ijisrt/26mar649

Vancouver

Shelke IB, Wanjari SS, Jaiswal AR. A Review on Targeting A-Synuclein Aggregation for Parkinson’s Disease Modification. International Journal of Innovative Science and Research Technology. 2026:1365. doi:10.38124/ijisrt/26mar649

BibTeX
@article{Shelke2026,
  author = {Shelke, I. B. and Wanjari, S. S. and Jaiswal, A. R.},
  title = {A Review on Targeting A-Synuclein Aggregation for Parkinson’s Disease Modification},
  journal = {International Journal of Innovative Science and Research Technology},
  year = {2026},
  pages = {1365},
  doi = {10.38124/ijisrt/26mar649}
}
Kostenlos starten →